-
Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
Cancer Cell. 2005 Mar;7(3):211-7
PMID: 15766659
-
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
Cancer Cell. 2005 May;7(5):411-23
PMID: 15894262
-
Treatment options for androgen-independent prostate cancer.
Clin Adv Hematol Oncol. 2003 Jan;1(1):49-57
PMID: 16227960
-
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Cancer Res. 2005 Dec 15;65(24):11565-71
PMID: 16357166
-
Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
Cell. 2006 Feb 24;124(4):823-35
PMID: 16497591
-
A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.
J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001
PMID: 16525037
-
Nuclear factor-kappaB in cancer development and progression.
Nature. 2006 May 25;441(7092):431-6
PMID: 16724054
-
Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure.
Immunity. 2006 Sep;25(3):499-509
PMID: 16934497
-
Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha.
Am J Epidemiol. 2006 Nov 15;164(10):984-9
PMID: 16931544
-
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
Nat Med. 2007 Jan;13(1):62-9
PMID: 17159986
-
Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Arthritis Rheum. 2007 Jan;56(1):117-28
PMID: 17195214
-
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.
Nature. 2007 Apr 5;446(7136):690-4
PMID: 17377533
-
Stat3 as a potential target for cancer immunotherapy.
J Immunother. 2007 Feb-Mar;30(2):131-9
PMID: 17471161
-
Fc-receptors as regulators of immunity.
Adv Immunol. 2007;96:179-204
PMID: 17981207
-
Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity.
J Immunol. 2008 Apr 1;180(7):4994-5003
PMID: 18354225
-
Cancer-related inflammation.
Nature. 2008 Jul 24;454(7203):436-44
PMID: 18650914
-
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.
Cancer Cell. 2008 Aug 12;14(2):156-65
PMID: 18691550
-
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Cancer Res. 2008 Aug 15;68(16):6762-9
PMID: 18701501
-
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8
PMID: 18723683
-
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.
Nature. 2009 Jan 1;457(7225):102-6
PMID: 19122641
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science. 2009 May 8;324(5928):787-90
PMID: 19359544
-
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.
Nat Med. 2009 Oct;15(10):1170-8
PMID: 19767732
-
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Cancer Res. 2000 Apr 15;60(8):2132-5
PMID: 10786674
-
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.
Mech Dev. 2001 Mar;101(1-2):61-9
PMID: 11231059
-
Interleukin-6 and prostate cancer progression.
Cytokine Growth Factor Rev. 2001 Mar;12(1):33-40
PMID: 11312117
-
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Leukemia. 2001 May;15(5):787-93
PMID: 11368440
-
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.
Science. 2001 Aug 24;293(5534):1495-9
PMID: 11520989
-
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
Nature. 2002 Jul 11;418(6894):191-5
PMID: 12110890
-
Inflammation and cancer.
Nature. 2002 Dec 19-26;420(6917):860-7
PMID: 12490959
-
Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting.
Immunol Rev. 2003 Oct;195:106-16
PMID: 12969314
-
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
Cancer Cell. 2003 Sep;4(3):223-38
PMID: 14522256
-
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.
Cancer Cell. 2004 Sep;6(3):297-305
PMID: 15380520
-
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers.
EMBO J. 2004 Oct 27;23(21):4202-10
PMID: 15470505
-
Prostate cancer in a transgenic mouse.
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
PMID: 7724580
-
Inducible gene targeting in mice.
Science. 1995 Sep 8;269(5229):1427-9
PMID: 7660125
-
B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5.
J Exp Med. 1998 Feb 16;187(4):655-60
PMID: 9463416
-
CD40 ligation and IL-4 use different mechanisms of transcriptional activation of the human lymphotoxin alpha promoter in B cells.
Eur J Immunol. 1998 Mar;28(3):901-6
PMID: 9541585
-
The biology of hormone refractory prostate cancer. Why does it develop?
Urol Clin North Am. 1999 May;26(2):263-73
PMID: 10361549
-
CXCL13 neutralization reduces the severity of collagen-induced arthritis.
Arthritis Rheum. 2005 Feb;52(2):620-6
PMID: 15692971